Intervacc AB (DE:2E9)
FRANKFURT:2E9
Want to see DE:2E9 full AI Analyst Report?
2E9 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EST
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€37.04M
Enterprise Value€287.56M
Total Cash (Recent Filing)€145.63M
Total Debt (Recent Filing)€357.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€4.05M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityVery low debt and a sizeable equity base provide durable financial flexibility, lowering refinancing and interest risk. This balance sheet strength supports continued R&D, manufacturing scale-up and commercial partnerships, giving the company runway to pursue growth before needing urgent external funding.
Commercialized Core Product (Strangvac)Owning an approved, commercial vaccine creates a recurring revenue engine and a defensible market position in veterinary vaccines. Regulatory approvals and manufacturing for Strangvac constitute structural barriers to entry and enable partner distribution agreements that can provide steady, long-term revenue if adoption expands.
Free Cash Flow Improving Vs Prior PeriodA substantial improvement in free cash flow indicates operational progress toward narrowing cash burn and better capital efficiency. If sustained, this trend reduces external financing needs, extends runway, and signals that commercial execution or cost control measures are beginning to have lasting impact.
Bears Say
Large Negative Operating And Free Cash FlowPersistently negative operating and free cash flow means the business cannot self-fund its operations or growth. This creates structural reliance on external capital, increases dilution and financing risk, and limits the company's ability to invest in commercialization or manufacturing without raising funds.
Negative Gross Profit And Extreme Operating LossesNegative gross profit and outsized operating losses reflect structural unit economics issues or high fixed costs relative to sales. Without material margin improvement or scale, losses will continue to erode equity and undermine long-term viability, necessitating product repricing, cost cuts or demand expansion.
Modest, Declining Revenue BaseA small and shrinking revenue base limits economies of scale and makes margin recovery harder. Declining top-line suggests adoption, pricing, or market penetration challenges for the commercial vaccine, reducing near-term prospects for self-sustaining profitability absent clear growth catalysts.
Intervacc AB News
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €37.04M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 89 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -€0.006 earnings per share for the quarter, the consensus estimate of -€0.006 by €0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.006 in its last earnings report, expectations of -€0.006. Following the earnings report the stock price went down -6.494%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―